Trafermin - Kaken Pharmaceutical - AdisInsight (original) (raw)
Alternative Names: CAB 2001; Fiblast Spray; KCB-1; KCB-1B; KCB-1D; REGROTH Dental Kit
Latest Information Update: 14 Sep 2018
Price : $50 *
- Adis is an information provider.We do not sell or distribute actual drugs.
- Final gross price and currency may vary according to local VAT and billing address.
- Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
- A link to download a PDF version of the drug profile will be included in your email receipt.
At a glance
- Originator Scios
- Developer Kaken Pharmaceutical; Olympus Corporation; Scios
- Class Fibroblast growth factors; Peptide fragments; Vascular disorder therapies
- Mechanism of Action Fibroblast growth factor stimulants
- Orphan Drug Status No
- New Molecular Entity Yes
Highest Development Phases
- Marketed Skin ulcer
- Registered Periodontitis
- Discontinued Coronary disorders; Diabetic foot ulcer; Fracture; Peripheral vascular disorders; Postmenopausal osteoporosis; Stroke
Most Recent Events
- 05 Sep 2018 Taxus Cardium Pharmaceuticals Group is now called Gene Biotherapeutics
- 28 Sep 2016 Registered for Periodontitis in Japan (Topical)
- 31 Dec 2014 Trafermin is still in phase III trials for Periodontitis in Japan (Topical, gel)
You need to be a logged in or subscribed to view this contentRequest demo
If your organization or you do not have a subscription, try one of the following:
- Contacting your organization’s admin about adding this content to your AdisInsight subscription
- Buying a PDF version of any individual profile
- Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
- Working within your organization’s network
- Login with username/password or try toaccess via your institution
- Persisted access using your organization’s identifier stored in your user browser for 90 days
For assistance, contact us atasktheexpert.adisinsight@springer.com